Safety Considerations with Fibrate Therapy

Fibrates are an important class of drugs for the management of dyslipidemia. This class of drugs is generally well tolerated but is infrequently associated with several safety issues. Fibrates, most likely by an effect mediated by peroxisome proliferator-activated receptor–α, may reversibly increase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2007-03, Vol.99 (6), p.S3-S18
Hauptverfasser:	Davidson, Michael H., MD, Armani, Annemarie, MD, McKenney, James M., PharmD, Jacobson, Terry A., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Cardiology Cardiovascular Cardiovascular disease Cholelithiasis - chemically induced Cholesterol Clinical outcomes Clinical trials Clinical Trials as Topic Clofibric Acid - adverse effects Clofibric Acid - pharmacology Clofibric Acid - therapeutic use Correlation analysis Creatinine - blood Drug therapy Drug Therapy, Combination Dyslipidemias - drug therapy Evidence-Based Medicine Humans Hypolipidemic Agents - adverse effects Hypolipidemic Agents - pharmacology Hypolipidemic Agents - therapeutic use Inhibitor drugs Kidney - drug effects Kidney - metabolism Lipids Peroxisome Proliferator-Activated Receptors - agonists Rhabdomyolysis - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Fibrates are an important class of drugs for the management of dyslipidemia. This class of drugs is generally well tolerated but is infrequently associated with several safety issues. Fibrates, most likely by an effect mediated by peroxisome proliferator-activated receptor–α, may reversibly increase creatinine and homocysteine but are not associated with an increased risk for renal failure in clinical trials. Fibrates are associated with a slightly increased risk (
ISSN:	0002-9149 1879-1913
DOI:	10.1016/j.amjcard.2006.11.016